mRNA Cancer Vaccines: Upgrading Your Immunity for Tomorrow

Traditional cancer treatments have focused entirely on targeting tumor cells directly. Today, a revolutionary approach, advancing through global clinical trials, is completely changing the game. mRNA cancer vaccines are training patients’ own immune system to independently destroy cancer cells from within.

This cutting-edge technology turns your body into its own defense mechanism, meaning its ultimate success relies heavily on a strong host. Because your everyday habits dictate how effectively your immune cells can respond to this breakthrough, upgrading your lifestyle is the vital first step toward maximising tomorrow's medicine.

The Scientific Breakthrough: What Is an mRNA Cancer Vaccine?

Unlike childhood jabs that prevent you from catching a disease, mRNA cancer vaccines are a form of treatment. They are given to people who already have cancer.

Think of the vaccine as a highly detailed instruction manual sent directly to your body. Written in mRNA (messenger ribonucleic acid), these instructions teach your immune system exactly how to hunt down and eliminate cancer cells from the inside out. 

How Does It Work?

Once you receive the vaccine, specialised immune cells read the instruction manual. They use it to build a harmless copy of a protein found on the cancer cells, showing your immune system exactly what cancer cells look like. Your body responds by activating two types of powerful immune cells:

• CD8-positive T cells (cytotoxic T cells): these directly destroy cancer cells

• CD4-positive T cells (helper T cells): these coordinate and strengthen the overall immune response

Once activated, these cells circulate throughout your body and seek out the cancer cells. As a bonus, your body can also remember this training, potentially keeping watch against cancer returning in the future.

Personalised to You

Cancer is unique to every individual, which is why these vaccines are custom-made. Scientists analyse the genetic makeup of a patient's tumour, then identify unique markers called neoantigens (proteins found only on that patient's cancer cells). The vaccine is then designed to target these specific markers, making the treatment highly individual, and this manufacturing process can be completed within a few weeks.

What Does the Research Show?

Results from clinical trials are highly encouraging, though these vaccines are still in the testing phase and are not yet available for routine medical use.

Skin cancer (melanoma)

A major clinical trial tested a personalised mRNA vaccine alongside an existing immune-boosting medicine called pembrolizumab. The results showed:

• Higher success rates: After 18 months, 78.6% of patients who got the vaccine combination were completely cancer-free.
• Better than standard care: In comparison, only 62.2% of patients who took the standard medicine alone remained cancer-free.
• Long-lasting protection: Recent 5-year follow-up data confirms that the vaccine continues to offer meaningful, long-term benefits. Large-scale global testing is now underway to confirm these findings in a much larger group of patients.

Pancreatic Cancer

An early-stage trial tested a personalised vaccine on patients right after they had surgery.

• Strong response: Half of the patients generated a powerful immune response to the vaccine.

• No recurrence: Every single patient who had that strong response remained completely cancer-free at the 18-month mark.

• Years of defense: Remarkably, the cancer-fighting immune cells created by the vaccine were still active and patrolling the body years later.

Is It Safe?

Based on trials reported to date, mRNA cancer vaccines have shown a favourable safety profile. The most commonly reported side effects are mild to moderate and include:

• Fatigue

• Fever

• Pain or redness at the injection site

Severe side effects are uncommon. Because mRNA does not enter the cell's nucleus and does not alter DNA, there is no risk of permanent genetic modification.

Before starting supplements, ask your doctor for a blood test. Taking them blindly without knowing your baseline can actually harm your immunity:

• Vitamin D: Low levels hurt outcomes; a simple test determines if you need a supplement to assist immunotherapy.

• Zinc: Vital for killer cell function, but taking too much can paradoxically suppress your immune system.

• Selenium: Helps immune cells mature, but can be harmful if your natural levels are already normal.

• Omega-3s: Eat oily fish 2–3 times a week. Avoid high-dose supplements, which can accidentally lower T-cell activity.

The Longevity Frontier: Looking Ahead at Personalised Medicine

mRNA cancer vaccines represent one of the most promising new directions in cancer care. By tailoring treatments to the unique genetic code of a patient's tumor, this technology provides a fast, precise, and highly personalised defense against disease.

However, this revolutionary vaccine requires an active partner in your body. Making intentional daily choices like prioritising sleep, staying active, and fueling your gut directly optimises the environment the vaccine needs to succeed. This innovative therapy transforms the future of cancer care through a powerful partnership with your everyday health. 

Dr Shiba Poon

General Practice, Family Medicine

• LMCHK
• MBBS (Lond)
• DRCOG
• DCH (RCPCH)
• PGDipClinDerm (Lond)
• MRCGP
• Honorary Clinical Assistant Professor In Family Medicine (HKU)

View Profile

Health Articles by Dr Shiba Poon

mRNA Cancer Vaccines: Upgrading Your Immunity for Tomorrow

Preventative Health: Biomarkers and Genetic Tests for Personalised Care

(Part 2) The Fat You Can't Always See: The Path to Metabolic Recovery

(Part 1) The Fat You Can't Always See: MASLD & Visceral Adiposity

Understanding CRP: A Marker of Chronic Inflammation

The Advanced Diet Detox Guide: How Glutathione Protects You

How to Reverse Type 2 Diabetes with Lifestyle Medicine

High Creatinine Levels: Normal Range and Management

Sleepless in Perimenopause: Is Low Progesterone to Blame?

Gut Health and Perimenopause: The Hidden Connection

The Science of IV Vitamin Therapy for Post-Surgery Recovery

Ferritin: You Don’t Have to Be Anaemic to Have Iron Deficiency

Hong Kong Longevity: Blue Zone Habits for Active Aging

Essential OTC Medicine Checklist for Home and Travel

Immune Dysfunction and Skin Rashes: Cause and Treatment

Lifestyle Medicine: Transform Your Health with The Six Core Pillars

Uric Acid Levels: Normal Range, Symptoms & Dietary Tips

Cholesterol-lowering Medication: Do You Need It for Life?

Post-Surgery Diet Guide: 5 Types of Foods That Aid in Wound Healing

References

1. Weber, J.S., Carlino, M.S., Khattak, A., Meniawy, T., Ansstas, G., Taylor, M.H., Kim, K.B., McKean, M., Long, G.V. and Sullivan, R.J. et al. (2024) 'Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study', The Lancet, 403(10427), pp. 632–644. DOI: 10.1016/S0140-6736(23)02268-7. Available at: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02268-7/fulltext [Accessed: 26 August 2026].
2. Carlino MS, et al. (2025) 'Three-year update of a randomized phase IIb study of the individualised neoantigen therapy intismeran autogene (mRNA-4157, V940) plus pembrolizumab versus pembrolizumab in resected melanoma', JCO Oncology Advances. DOI: 10.1200/OA-25-00008. Available at: https://ascopubs.org/doi/10.1200/OA-25-00008 [Accessed: 26 August 2026].
3. Khattak, A., Carlino, M.S., Meniawy, T., Ansstas, G., Taylor, M.H., Kim, K.B., McKean, M., Long, G.V., Sullivan, R.J. and Faries, M. et al. (2026) 'Intismeran autogene plus pembrolizumab versus pembrolizumab alone in high-risk resected melanoma: 5-year update of the randomized phase IIb KEYNOTE-942 study', Journal of Clinical Oncology. DOI: 10.1200/JCO-26-00835. Available at: https://ascopubs.org/doi/10.1200/JCO-26-00835 [Accessed: 26 August 2026].
4. Rojas, L.A., Sethna, Z., Soares, K.C., Olcese, C., Pang, N., Patterson, E., Lihm, J., Ceglia, N., Guasp, P. and Chu, A. et al. (2023) 'Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer', Nature, 618(7963), pp. 144–150. DOI: 10.1038/s41586-023-06063-y. Available at: https://www.nature.com/articles/s41586-023-06063-y [Accessed: 26 August 2026].
5. Sethna, Z., Guasp, P., Reiche, C., Milighetti, M., Ceglia, N., Patterson, E., Lihm, J., Payne, G., Lyudovyk, O. and Rojas, L.A. et al. (2025) 'RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer', Nature, 639, pp. 1042–1051. DOI: 10.1038/s41586-024-08508-4. Available at: https://www.nature.com/articles/s41586-024-08508-4 [Accessed: 26 August 2026].
6. Besedovsky, L., Lange, T. and Haack, M. (2019) 'The sleep–immune crosstalk in health and disease', Physiological Reviews, 99(3), pp. 1325–1380. DOI: 10.1152/physrev.00010.2018. Available at: https://journals.physiology.org/doi/abs/10.1152/physrev.00010.2018 [Accessed: 26 August 2026].
7. Liu, X.F., Zhu, X.D., Feng, L.H., Li, X.L., Xu, B., Li, K.S., Xiao, N., Lei, M., Sun, H.C. and Tang, Z.Y. (2022) 'Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model', Experimental Hematology and Oncology, 11, article 20. DOI: 10.1186/s40164-022-00275-0. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8978397 [Accessed: 26 August 2026].
8. Spencer, C.N., McQuade, J.L., Gopalakrishnan, V., McCulloch, J.A., Vetizou, M., Cogdill, A.P., Khan, A.W., Zhang, X., White, M.G. and Peterson, C.B. et al. (2021) 'Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response', Science, 374(6575), pp. 1632–1640. DOI: 10.1126/science.aaz7015. Available at: https://www.science.org/doi/10.1126/science.aaz7015 [Accessed: 26 August 2026].
9. Matthews, N.C., Faith, A., Pfeffer, P., Lu, H., Kelly, F.J., Hawrylowicz, C.M. and Lee, T.H. (2014) 'Urban particulate matter suppresses priming of T helper type 1 cells by granulocyte/macrophage colony-stimulating factor-activated human dendritic cells', American Journal of Respiratory Cell and Molecular Biology, 50(2), pp. 281–291. DOI: 10.1165/rcmb.2012-0465OC. Available at: https://pubmed.ncbi.nlm.nih.gov/24010813/ [Accessed: 26 August 2026].
10. Balali-Mood, M., Naseri, K., Tahergorabi, Z., Khazdair, M.R. and Sadeghi, M. (2021) 'Toxic mechanisms of five heavy metals: mercury, lead, chromium, cadmium, and arsenic', Frontiers in Pharmacology, 12, article 643972. DOI: 10.3389/fphar.2021.643972. Available at: https://www.frontiersin.org/articles/10.3389/fphar.2021.643972/full [Accessed: 26 August 2026].
11. Yang, Q., Shu, C., Li, H., Xie, X., Wu, H., Zhou, Y., Hu, H., Zhao, J., Xu, C. and He, Y. (2025) 'Higher serum vitamin D concentration and supplementation were associated with improved survival outcomes and treatment response in cancer patients receiving immunotherapy: a systematic review and meta-analysis', Nutrition Research, 141, pp. 82–95. DOI: 10.1016/j.nutres.2025.08.003. Available at: https://doi.org/10.1016/j.nutres.2025.08.003 [Accessed: 26 August 2026].
12. Bonaventura, P., Benedetti, G., Albarède, F. and Miossec, P. (2015) 'Zinc and its role in immunity and inflammation', Autoimmunity Reviews, 14(4), pp. 277–285. DOI: 10.1016/j.autrev.2014.11.008. Available at: https://www.sciencedirect.com/science/article/abs/pii/S1568997214002808?via%3Dihub [Accessed: 26 August 2026].
13. Lippman, S.M., Klein, E.A., Goodman, P.J., et al. (2009) 'Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)', JAMA, 301(1), pp. 39–51. DOI: 10.1001/jama.2008.864. Available at: https://jamanetwork.com/journals/jama/fullarticle/183163 [Accessed: 26 August 2026].